科濟藥業-B(02171.HK:於2024年EHA年會上呈列賽愷澤®II期臨牀試驗和 CT071首次人體試驗的研究成果更新
格隆匯6月17日丨科濟藥業-B(02171.HK)發佈公吿,賽愷澤® (澤沃基奧侖賽注射液,產品編號: CT053,一種靶向BCMA的自體CAR-T細胞產品)和CT071(一種靶向G蛋白偶聯受體C組5成員D(GPRC5D)的自體CAR-T細胞候選產品)的更新結果已在第29屆歐洲血液學協會(“EHA”)年會上進行報吿。
賽愷澤®LUMMICAR STUDY 1研究結果已於歐洲中部夏令時間2024年6月15 日17:30-17:45,在第29屆EHA年會上進行口頭報吿,標題為“針對複發性 ╱ 難治性多發性骨髓瘤患者的全人源BCMA靶向CAR-T細胞(zevorcabtagene autoleucel)的2期研究”(“Phase 2 study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed/refractory multiple myeloma”)。
CT071 I期初步研究結果已於歐洲中部夏令時間2024年6月14日18:00-19:00,在第29屆EHA年會上進行壁報展示,標題為“快速生產的靶向GPRC5D的CAR-T 細胞產品(CT071)在復發 ╱ 難治性多發性骨髓瘤患者中的首次人體研究”(“Firstin-human study of GPRC5D-targeted CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/refractory multiple myeloma (RRMM))。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.